News
RANI
0.7630
+2.79%
0.0207
Weekly Report: what happened at RANI last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at RANI last week (0608-0612)?
Weekly Report · 06/15 10:40
Weekly Report: what happened at RANI last week (0601-0605)?
Weekly Report · 06/08 10:35
Weekly Report: what happened at RANI last week (0525-0529)?
Weekly Report · 06/01 10:41
Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
TipRanks · 06/01 10:15
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
TipRanks · 05/29 11:42
Rani Therapeutics stockholders elect directors at annual meeting
PUBT · 05/29 10:04
Rani Therapeutics Announces $20 Million Equity Financing
TipRanks · 05/27 10:39
Rani Announces Pricing Of $20 Mln Direct Offering At $1.07 Per Share; Stock Down
NASDAQ · 05/26 15:46
Rani Therapeutics to raise $20M in registered direct offering
Seeking Alpha · 05/26 12:31
Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share
Benzinga · 05/26 12:04
RANI THERAPEUTICS HOLDINGS, INC. ANNOUNCES PRICING OF $20.0 MILLION REGISTERED DIRECT OFFERING OF CLASS A COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 05/26 12:00
Weekly Report: what happened at RANI last week (0518-0522)?
Weekly Report · 05/25 10:45
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 05/20 14:45
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity
Dow Jones · 05/20 14:45
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Alpha Tau Medical Ltd (DRTS) and Protara Therapeutics (TARA)
TipRanks · 05/20 10:50
Lake Street Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)
TipRanks · 05/19 08:37
Weekly Report: what happened at RANI last week (0511-0515)?
Weekly Report · 05/18 10:45
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
TipRanks · 05/17 06:00
Rani Therapeutics CFO Sanford to depart
Seeking Alpha · 05/15 21:00
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).